US · Healthcare · Biotechnology
EPS came in at -0.80 against a street estimate of -0.69 — a miss of 15.9%.
Analysts rate Vor Biopharma Inc a strong buy (8 buy, 1 hold, 0 sell out of 9) with an average price target of $39.00.
| Fund | Stake |
|---|---|
| TCG Crossover Management, LLC | 9.59% |
| FMR Inc | 8.34% |
| FCPM III SERVICES BV | 6.96% |
| BlackRock Inc | 5.86% |
| VR Adviser, LLC | 5.14% |
| State Street Corp | 4.42% |
| Frazier Life Sciences Management, L.P. | 4.30% |
| RA Capital Management, LLC | 4.06% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 VOR BIOPHARMA INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Liquidity: $107.9 million in cash and $358.3 million in marketable securities as | 2026-08-11 |
| Board / officer change · Q3 2026 VOR BIOPHARMA INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Vor Biopharma Inc. (Nasdaq: VOR) • Filing Date: July 7, 2026 • Report covers events fro | 2026-07-07 |
| Shareholder vote results · Q2 2026 VOR BIOPHARMA INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 11, 2026 with 34,012,004 shares present or represented (62.77% of votin | 2026-06-12 |
| Reg FD disclosure · Q2 2026 VOR BIOPHARMA INC. – 8-K SUMMARY HEADLINE NUMBERS • Company: Vor Biopharma Inc. (ticker: VOR, Nasdaq Global Select Market) • Report Date: June 8, 20 | 2026-06-08 |
| Quarterly report · Q1 2026 VOR BIOPHARMA INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $169.9 million in cash and cash equivalents plus $321.7 million in marke | 2026-05-13 |
| Proxy statement · Q2 2026 VOR BIOPHARMA INC. – 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two Class II director nominees (three-yea | 2026-04-27 |
| Annual report FY2025 VOR BIOPHARMA INC. — ANNUAL REPORT SUMMARY (FISCAL YEAR ENDED DECEMBER 31, 2025) HEADLINE NUMBERS • Market capitalization as of June 30, 2025: appro | 2026-03-30 |
| Material agreement · Q1 2026 VOR BIOPHARMA INC. - 8-K SUMMARY HEADLINE NUMBERS • Private placement financing: $75.0 million gross proceeds from sale of 5,338,078 common shares a | 2026-03-27 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vor Biopharma Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.